June 5, 2017 Lab Top-10 M&A, Partnerships Mass Spectrometry

Shimadzu Corporation and Phytronix Technologies sign an agreement to offer the first Triple Ion Source (LDTD-MS/MS, ESI-MS/MS and APCI-MS/MS).

Kyoto, Japan and Québec, Canada – June 5, 2017. Shimadzu, one of the world’s fastest growing mass spectrometry companies, and Phytronix, world leader in high throughput analysis in mass spectrometry, announce today that they have signed an agreement to offer the industry’s first Triple Ion Source. Ideal for both screening and confirmation work, this new... Read more

June 5, 2017 Liq. Handling & Robotics M&A, Partnerships

Thermo Fisher Scientific and Biognosys Announce Co-Marketing Agreement to Create Industry-Leading Data-Independent Acquisition Workflows

Thermo Fisher Scientific Inc., the world leader in serving science, today announced a co-marketing agreement with Biognosys AG, leader in next-generation proteomics, to provide a comprehensive, efficient workflow to enable library creation and data processing for Data-Independent Acquisition (DIA) studies, through the combined use of Orbitrap mass spectrometers and Spectronaut Pulsar software. Compatible with the... Read more

June 5, 2017 Lab Top-10 Licensing, IP, and Legal M&A, Partnerships

Shimadzu Corporation and Phytronix Technologies sign an agreement to offer the first Triple Ion Source (LDTD-MS/MS, ESI-MS/MS and APCI-MS/MS).

Kyoto, Japan and Québec, Canada – June 5, 2017. Shimadzu, one of the world’s fastest growing mass spectrometry companies, and Phytronix, world leader in high throughput analysis in mass spectrometry, announce today that they have signed an agreement to offer the industry’s first Triple Ion Source. Ideal for both screening and confirmation work, this new... Read more

June 3, 2017 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

NEW YORK and HILDEN, Germany, (June 3, 2017) – Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN(NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as  predictive or prognostic tools for  use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in... Read more

June 2, 2017 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics

Agreement Accelerates the Development of Tests to Help Assess Risk of Disease Recurrence in Women with Early-Stage Breast Cancer SANTA CLARA, Calif., June 2, 2017 Agilent Technologies Inc. (NYSE: A) and Agendia, Inc. today jointly announced an agreementto expand their relationship to include the development of an RNA-Seq kit version of Agendia’s currently marketed MammaPrint... Read more

June 2, 2017 M&A, Partnerships

Xylem affirms its strong support for the Paris Climate Agreement

RYE BROOK, N.Y.–(BUSINESS WIRE)–Jun. 1, 2017– Following today’s announcement that the United States will withdraw from the Paris Climate Agreement, Xylem, a leading global water technology company, issued the following statement: “Addressing the realities of climate change is an opportunity to create shared value among all stakeholders, and Xylem remains committed to doing our part... Read more

June 1, 2017 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Philips and Illumina team up with Navican, an Intermountain Healthcare Company, to Accelerate the Delivery of Precision Medicine to Health Systems Worldwide

– New “turnkey” approach to precision medicine seeks to deliver Intermountain’s best practices into a streamlined service to be integrated at the point of care – Solution’s goal is to benefit late stage cancer patients through advanced analytics and expert decision support, combined with providing better access to targeted treatments and clinical trials NEWS PROVIDED... Read more

May 31, 2017 Chromatography Lab Top-10 M&A, Partnerships Molecular Spectroscopy

Waters and Wyatt Collaborate to Advance Polymer Analysis and Biopharmaceutical Characterization Studies

Coupling of technologies delivers valuable information 5x faster than conventional size exclusion chromatography (SEC) MILFORD, Mass.–(BUSINESS WIRE)–May 31, 2017– Waters Corporation (NYSE:WAT) announced that it entered into a Co-Marketing agreement with Wyatt Technology to advance the analysis of synthetic polymers and biotherapeutic proteins. By pairing Waters® ACQUITY® UPLC® and Waters® ACQUITY® Advanced Polymer Chromatography® (APC™)... Read more